Neuroendocrine Neoplasms Clinical Trials

8 recruiting

Neuroendocrine Neoplasms Trials at a Glance

13 actively recruiting trials for neuroendocrine neoplasms are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Phase 1 with 6 trials, with the heaviest enrollment activity in Barcelona, Atlanta, and Madrid. Lead sponsors running neuroendocrine neoplasms studies include Boehringer Ingelheim, National Cancer Institute (NCI), and King's College Hospital NHS Trust.

Browse neuroendocrine neoplasms trials by phase

Treatments under study

About Neuroendocrine Neoplasms Clinical Trials

Looking for clinical trials for Neuroendocrine Neoplasms? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neuroendocrine Neoplasms trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neuroendocrine Neoplasms clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 1

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Neuroendocrine Neoplasms
Boehringer Ingelheim55 enrolled19 locationsNCT06132113
Recruiting
Phase 1

A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
Boehringer Ingelheim300 enrolled12 locationsNCT04429087
Recruiting
Phase 2

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Neuroendocrine TumorsParagangliomaPheochromocytoma+1 more
National Cancer Institute (NCI)130 enrolled1 locationNCT03206060
Recruiting
Phase 2

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Neuroendocrine NeoplasmsSmall Cell Lung CarcinomaExtra-pulmonary Neuroendocrine Carcinoma
Boehringer Ingelheim204 enrolled59 locationsNCT05882058
Recruiting
Phase 1Phase 2

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Neuroendocrine TumorsNeuroendocrine NeoplasmsGastroenteropancreatico Tumors
National Cancer Institute (NCI)56 enrolled1 locationNCT04086485
Recruiting
Phase 1Phase 2

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Neuroendocrine NeoplasmNeuroendocrine TumorsSST2-positive Neuroendocrine Neoplasms
Crinetics Pharmaceuticals Inc.150 enrolled21 locationsNCT07129252
Recruiting
Phase 1

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Small Cell Lung Cancer Metastatic or Locally AdvancedNeuroendocrine CancerMetastatic or Locally Advanced Neuroendocrine Prostate Cancer+5 more
SystImmune Inc.120 enrolled20 locationsNCT07080242
Recruiting
Phase 2

Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors

Neuroendocrine TumorsNeuroendocrine Neoplasms (Tumours)Metastatic Neuroendocrine Tumors
Tata Memorial Hospital20 enrolled2 locationsNCT07404176
Recruiting
Phase 4

Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms

Neuroendocrine TumorsNeuroendocrine Neoplasms
Shanghai Zhongshan Hospital350 enrolled4 locationsNCT07272512
Recruiting
Phase 2

Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)

High Grade Neuroendocrine Neoplasms
Washington University School of Medicine32 enrolled2 locationsNCT06926634
Recruiting
Phase 1

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

Small Cell Lung Carcinoma (SCLC)Neuroendocrine Neoplasms
Boehringer Ingelheim12 enrolled1 locationNCT05963867
Recruiting

Collection of Liquid Biopsy Samples of Neuroendocrine Neoplasms (NEN) Patients - Collection of NET (CollectNET) 2.0, a Study by the BE-FORCE Consortium

Neuroendocrine Neoplasms
University Hospital, Antwerp550 enrolled8 locationsNCT06541080
Recruiting

Mobile Application to Collect PRO Data in NET Patients

Neuroendocrine Neoplasms (Tumours)
King's College Hospital NHS Trust2,000 enrolled1 locationNCT04324502